SCHEMBL557792

SCHEMBL557792

Cc1ccc2nc(N)oc2c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 1/20 0.61
RAB9A P51151 8/20 0.60
NPC1 O15118 7/20 0.60
KDM4E B2RXH2 6/20 0.60
SMN1; SMN2 Q16637 6/20 0.60
MAPT P10636 6/20 0.60
ALDH1A1 P00352 5/20 0.60
HPGD P15428 5/20 0.60
MEN1 O00255 1/20 0.60
KMT2A Q03164 1/20 0.60
TDP1 Q9NUW8 1/20 0.60
HSD17B10 Q99714 4/20 0.56
USP2 O75604 1/20 0.55
MAPK10 P53779 1/20 0.55
RPS6KA3 P51812 1/20 0.53
LCK P06239 1/20 0.51
TP53 P04637 2/20 0.50
PKM P14618 1/20 0.50
CYP1A2 P05177 2/20 0.47
CYP3A4 P08684 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31119200 0.84 MAPT (0.61) PIK3CGRAB9ANPC1KDM4ESMN1; SMN2
SCHEMBL12261 0.84 MAPT (0.61) PIK3CGRAB9ANPC1KDM4ESMN1; SMN2
SCHEMBL10950114 0.79 PIK3CG (0.66) PIK3CGRAB9ANPC1KDM4ESMN1; SMN2
SCHEMBL4390043 0.79 PIK3CG (0.66) PIK3CGRAB9ANPC1KDM4ESMN1; SMN2
SCHEMBL5541680 0.79 KDM4E (0.63) RAB9ANPC1KDM4ESMN1; SMN2MAPT
SCHEMBL15582914 0.76 PIK3CG (0.61) PIK3CGRAB9ANPC1KDM4ESMN1; SMN2
SCHEMBL7893733 0.76 PIK3CG (0.61) PIK3CGRAB9ANPC1KDM4ESMN1; SMN2
SCHEMBL21983971 0.76 PIK3CG (0.61) PIK3CGRAB9ANPC1KDM4ESMN1; SMN2
SCHEMBL30988526 0.76 PIK3CG (0.61) PIK3CGRAB9ANPC1KDM4ESMN1; SMN2
SCHEMBL9898426 0.76 PIK3CG (0.61) PIK3CGRAB9ANPC1KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240174651-A1 COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED 2024-05-30 US disclosed
CN-117355303-A Compounds and their use for the treatment of neurodegenerative, degenerative and metabolic disorders 佛罗里达大学研究基金会公司 2024-01-05 CN disclosed
EP-4284372-A1 COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS University of Florida Research Foundation, Incorporated (US) 2023-12-06 EP disclosed
US-11639337-B2 Bicyclic heteroaryl derivatives and preparation and uses thereof XWPharma Ltd. (KY) 2023-05-02 US disclosed
WO-2022165173-A1 COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS THE SCRIPPS RESEARCH INSTITUTE (US) 2022-08-04 WO disclosed
WO-2022140456-A1 SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS MEKANISTIC THERAPEUTICS LLC (US) 2022-06-30 WO disclosed
WO-2021113686-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION (US) 2021-06-10 WO disclosed
WO-2021113690-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION (US) 2021-06-10 WO disclosed
WO-2021113682-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION (US) 2021-06-10 WO disclosed
WO-2021113698-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION (US) 2021-06-10 WO disclosed
US-20080200495-A1 Pyrrolopyridine Compounds, Method of Making Them and Uses Thereof LABORATOIRES FOURNIER S.A. (FR) 2008-08-21 US disclosed
US-20080176833-A1 DIHYDROPYRIDINE DERIVATIVES AS USEFUL AS PROTEIN KINASE INHIBITORS BAYER INTELLECTUAL PROPERTY GMBH (DE) 2008-07-24 US disclosed
US-20080176833-A1 DIHYDROPYRIDINE DERIVATIVES AS USEFUL AS PROTEIN KINASE INHIBITORS BAYER INTELLECTUAL PROPERTY GMBH (DE) 2008-07-24 US disclosed
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LABORATOIRES FOURNIER S.A. (FR) 2008-06-26 US disclosed
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LABORATOIRES FOURNIER S.A. (FR) 2008-06-26 US disclosed
WO-2008071451-A1 DIHYDROPYRIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-06-19 WO disclosed
US-20070207395-A1 Electrophotoconductor and image forming apparatus SHARP KABUSHIKI KAISHA (JP) 2007-09-06 US disclosed
US-20070207395-A1 Electrophotoconductor and image forming apparatus SHARP KABUSHIKI KAISHA (JP) 2007-09-06 US disclosed
WO-2007026104-A1 PYRROLOPYRIDINE DERIVATIVES AND USE OF SAME AS PPAR RECEPTOR MODULATORS LABORATOIRES FOURNIER S.A. (FR) 2007-03-08 WO disclosed
WO-2007026097-A1 NOVEL INDOLE COMPOUNDS LABORATOIRES FOURNIER S.A. (FR) 2007-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240174651-A1 COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS NLN, OAT, PC PIK3CG 3194/4885RAB9A 2299/4885NPC1 139/4885
US-20080200495-A1 Pyrrolopyridine Compounds, Method of Making Them and Uses Thereof LIPG, PCSK9, PNLIP PIK3CG 448/4885RAB9A 2673/4885NPC1 199/4885
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LIPG, GPR119, IAPP PIK3CG 844/4885RAB9A 2656/4885NPC1 96/4885
US-20080176833-A1 DIHYDROPYRIDINE DERIVATIVES AS USEFUL AS PROTEIN KINASE INHIBITORS MET, DMPK, RET PIK3CG 1611/4885RAB9A 1898/4885NPC1 3613/4885
US-11639337-B2 Bicyclic heteroaryl derivatives and preparation and uses thereof GRIN2A, GRIN2C, GRIN3A PIK3CG 1975/4885RAB9A 960/4885NPC1 559/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.